Efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole in the treatment of acute cerebral infarction: A systematic review and meta-analysis.
{"title":"Efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole in the treatment of acute cerebral infarction: A systematic review and meta-analysis.","authors":"Yangting Lyu, Bin Xu","doi":"10.1097/MD.0000000000040223","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To evaluate the clinical efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole (GLED) versus edaravone alone in the treatment of acute cerebral infarction (ACI) by the method of meta-analysis.</p><p><strong>Methods: </strong>PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, WANFANG DATA, and Chinese Scientific Journal Database were searched to identify publications on edaravone combined with GLED for ACI from inception to June 20, 2024. Stata15.0 statistical software was applied for data analysis. The test group was treated with edaravone combined with GLED, while the control group received edaravone alone.</p><p><strong>Results: </strong>A total of 12 records were involved in this meta-analysis. The combined results exhibited that the effective rate of edaravone combined with GLED was significantly higher than that of edaravone in the treatment of ACI (relative risk = 1.21, 95% confidence interval [CI] = 1.15-1.27, P < .001). The National Institute of Health stroke scale scores of edaravone combined with GLED were significantly lower than those of edaravone alone in the treatment of ACI (standardized mean difference = -1.93, 95% CI = -3.36 to -0.50, P = .008). The incidence of adverse reactions in the edaravone combined with GLED group was significantly lower than that in the edaravone alone group (relative risk = 0.48, 95% CI = 0.33-0.70, P < .001) in the treatment of ACI.</p><p><strong>Conclusion: </strong>The combination of edaravone with GLED for treating ACI has better efficacy and higher safety than edaravone alone. Given the limited number of studies identified and possibility of publication bias, the above findings should be verified by more high-quality trials in the future.</p>","PeriodicalId":18549,"journal":{"name":"Medicine","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537593/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MD.0000000000040223","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To evaluate the clinical efficacy and safety of edaravone combined with Ginkgo Leaf Extract and Dipyridamole (GLED) versus edaravone alone in the treatment of acute cerebral infarction (ACI) by the method of meta-analysis.
Methods: PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, WANFANG DATA, and Chinese Scientific Journal Database were searched to identify publications on edaravone combined with GLED for ACI from inception to June 20, 2024. Stata15.0 statistical software was applied for data analysis. The test group was treated with edaravone combined with GLED, while the control group received edaravone alone.
Results: A total of 12 records were involved in this meta-analysis. The combined results exhibited that the effective rate of edaravone combined with GLED was significantly higher than that of edaravone in the treatment of ACI (relative risk = 1.21, 95% confidence interval [CI] = 1.15-1.27, P < .001). The National Institute of Health stroke scale scores of edaravone combined with GLED were significantly lower than those of edaravone alone in the treatment of ACI (standardized mean difference = -1.93, 95% CI = -3.36 to -0.50, P = .008). The incidence of adverse reactions in the edaravone combined with GLED group was significantly lower than that in the edaravone alone group (relative risk = 0.48, 95% CI = 0.33-0.70, P < .001) in the treatment of ACI.
Conclusion: The combination of edaravone with GLED for treating ACI has better efficacy and higher safety than edaravone alone. Given the limited number of studies identified and possibility of publication bias, the above findings should be verified by more high-quality trials in the future.
期刊介绍：
Medicine is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties.
As an open access title, Medicine will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine’s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
